TY - JOUR T1 - Return to play after treating acute muscle injuries in elite football players with a multimodal therapy approach that includes a specific protocol of (almost) daily radial extracorporeal shock wave therapy JF - medRxiv DO - 10.1101/2020.02.18.20024653 SP - 2020.02.18.20024653 AU - James P.M. Morgan AU - Mario Hamm AU - Christoph Schmitz AU - Matthias H. Brem Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/02/20/2020.02.18.20024653.abstract N2 - Aim To compare lay-off times achieved by treating acute muscle injuries in elite football players with a multimodal therapy approach that includes a specific protocol of almost daily radial extracorporeal shock wave therapy (rESWT)) with corresponding data reported in the literature.Methods We performed a retrospective analysis of treatments and recovery times of muscle injuries suffered by the players of an elite football team competing in the first/second German Bundesliga during one of the previous seasons.Results A total of 20 acute muscle injuries were investigated in the aforementioned season, of which eight (40%) were diagnosed as type 1a/muscular tightness injuries, five (25%) as type 2b/muscle strain injuries, four (20%) as type 3a/partial muscle tear injuries and three (15%) as contusions. All injuries were treated with the previously mentioned multimodal therapy approach. Compared with data reported by Ekstrand et al. (Br J Sports Med 2013;47:769-774), lay-off times (median / mean) were shortened by 54% and 58% respectively in the case of type 1a injuries, by 50% and 55% respectively in the case of type 2b injuries as well as by 8% and 21% respectively in the case of type 3a injuries. No adverse reactions were observed.Conclusions Overall, the multimodal therapy approach investigated in this study is a safe and effective treatment approach for treating type 1a and 2b acute muscle injuries amongst elite football players and may help to prevent more severe, structural muscle injuries.What are the findings?➢ By treating acute muscle injuries suffered by the players of an elite football team competing in the first/second German Bundesliga during one of the previous seasons with a multimodal therapy approach (comprising cryotherapy, compression, manual therapy, resistance/weight-training, a progressive physiotherapy exercise programme and a specific protocol of (almost) daily radial extracorporeal shock wave therapy (rESWT)) we achieved median and mean lay-off times after type 1a (muscular tightness/hypertonicity) and 2b (muscular strain injury) muscle injuries that were 50% shorter than corresponding data reported in the literature (Ekstrand et al., Brit J Sports Med 2013;47:769-774).➢ The percentage of structural muscle injuries, specifically type 3 (partial muscle tear according to the Müller-Wohlfahrt/Munich muscle injury classification) and type 4 (complete muscle tear and/or avulsion injury involving the tendon) amongst this sample group of players (including injury types 1-4 as classified by Müller-Wohlfahrt et al; and excluding contusions) that occurred during the entire season comprised 23.5% of all the muscle injuries suffered. In comparison, the percentage of structural muscle injuries amongst similar sample groups of elite football players has been found to be considerably higher - in the data set reported by Ekstrand et al. (2013) higher grade structural muscle injuries amongst elite European football teams typically make up 66.9% of all muscle injuries suffered during the course of one season.How might it impact on clinical practice in the future?Our findings emphasise the effective use of a multimodal therapy approach (comprising cryotherapy, compression, manual therapy, resistance/weight-training, a progressive physiotherapy exercise programme and a specific protocol of (almost) daily rESWT for substantially shortening lay-off times associated with functional/ultrastructural muscle injuries and possibly for preventing more severe structural muscle injuries amongst sportspeople.Competing Interest StatementJames P.M. Morgan, Mario Hamm and Matthias H. Brem are employees of 1. FC Nuremberg Football Club (Nuremberg, Germany) where this study was performed. Christoph Schmitz has received research funding from Electro Medical Systems (Nyon, Switzerland) (the distributor of the Swiss DolorClast rESWT and Swiss PiezoClast fESWT devices) for his preclinical research at LMU Munich (unrestricted grant) and consulted (until December 31, 2017) for Electro Medical Systems. Furthermore, Electro Medical Systems provided the rESWT and fESWT devices used in this study. However, 1. FC Nuremberg Football Club and Electro Medical Systems had no role in study design, data collection and analysis, interpretation of the data, and no role in the decision to publish and write this manuscript. No other potential conflicts of interest relevant to this article were reported.Funding StatementThe study did not receive external funding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to confidentiality reasons, there are no data that can be shared except for those that are provided in the manuscript. ER -